These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 34716240)

  • 21. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
    Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
    Front Immunol; 2022; 13():892277. PubMed ID: 35669765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
    Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J
    Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
    Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E
    Front Immunol; 2021; 12():760249. PubMed ID: 34925330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
    Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
    Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.
    Garcia P; Anand S; Han J; Montez-Rath ME; Sun S; Shang T; Parsonnet J; Chertow GM; Schiller B; Abra G
    J Am Soc Nephrol; 2022 Jan; 33(1):33-37. PubMed ID: 34645698
    [No Abstract]   [Full Text] [Related]  

  • 28. Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients.
    Blazquez-Navarro A; Safi L; Meister TL; Thieme CJ; Kaliszczyk S; Paniskaki K; Stockhausen M; Hörstrup J; Cinkilic O; Flitsch-Kiefner L; Marheinecke C; Steinmann E; Seibert FS; Stervbo U; Westhoff TH; Pfaender S; Roch T; Babel N
    Kidney Int; 2021 Sep; 100(3):698-700. PubMed ID: 34273381
    [No Abstract]   [Full Text] [Related]  

  • 29. Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: the COViNEPH Project.
    Tylicki L; Biedunkiewicz B; Dąbrowska M; Ślizień W; Tylicki P; Polewska K; Rosenberg I; Rodak S; Dębska-Ślizień A
    Pol Arch Intern Med; 2021 Sep; 131(9):797-801. PubMed ID: 34351091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M
    EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses.
    Anft M; Blazquez-Navarro A; Frahnert M; Fricke L; Meister TL; Roch T; Stervbo U; Pfaender S; Westhoff TH; Babel N
    Kidney Int; 2022 Jul; 102(1):207-208. PubMed ID: 35580654
    [No Abstract]   [Full Text] [Related]  

  • 34. Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum.
    Quiroga B; Soler MJ; Ortiz A; Orero E; Tejedor S; Mantecón CJJ; Gómez Pérez VO; Marín Franco AJ; Alfaro Sánchez C; Puerta Carretero M; Jaldo Rodríguez MT; Carnerero Di Riso MA; Martínez S; González CC; Cervienka M; Macías Carmona N; Arroyo D; Pérez Del Valle KM; de Arriba G; Mazuecos A; Cazorla JM; Pereira M; González Parra E; Sánchez Márquez MG; Lancho Novillo C; Toyos Ruiz C; Aguilar Cervera MC; Muñoz Ramos P; Sánchez Horrillo A; Jimeno Martín I; Toapanta N; Cigarrán Guldris S; Folgueiras López M; Valero San Cecilio R; Villacorta Linaza B; Minguela Pesquera I; Santana Estupiñán R; Zamora R; Soriano S; Muñoz de Bustillo E; Pizarro Sánchez MS; Martínez Puerto AI; Yugueros A; Muñiz Pacios L; Leyva A; Rojas J; Gansevoort RT; de Sequera P;
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):872-876. PubMed ID: 35551070
    [No Abstract]   [Full Text] [Related]  

  • 35. Study of humoral and cellular immunity in vaccinated with mRNA-1273.
    Gutiérrez-Bautista JF; López-Nevot MÁ; Gómez-Vicente E; Quesada T; Marín EM; Rodríguez A; Rodríguez AI; Rodríguez-Granger J; Cobo F; Sampedro A
    APMIS; 2022 May; 130(5):261-269. PubMed ID: 35196403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
    Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
    Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
    Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
    Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.